Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes
Combined use of an SGLT2 inhibitor and GLP-1 receptor agonist is associated with reduced odds for major adverse cardiac and cerebrovascular events and heart failure in adults with type 2 diabetes, according to study findings. In an analysis of data from more than 300,000 adults with type 2 diabetes registered in three medical databases in England and Wales, the use of an SGLT2 inhibitor alone or